WuXi increases GMP plasmid DNA services

By The Science Advisory Board staff writers

November 12, 2020 -- WuXi Advanced Therapies has expanded its cell and gene therapy platforms with capabilities to provide high-quality and cost-effective good manufacturing practice (GMP) plasmids.

With these enhanced capabilities, the company can assist customers in overcoming current plasmid DNA supply constraints and expediting research and development and manufacturing processes of cell and gene therapy applications. WuXi is able to leverage its experience in testing of raw materials and biotherapeutics as well as in-house quality control and analytical services to ensure the safety of well-characterized and fully released plasmids.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.